Tackling myocardial infarction

Drug and Therapeutics Bulletin

Volumn 38, Issue 3, 2000, Pages 17-22

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; AMIODARONE; ANISTREPLASE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIAMORPHINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DUTEPLASE; ENALAPRIL; FIBRINOLYTIC AGENT; FLECAINIDE; HEPARIN; INSULIN; LIDOCAINE; LISINOPRIL; MAGNESIUM; METOCLOPRAMIDE; METOPROLOL; NITRATE; QUINIDINE; RAMIPRIL; RETEPLASE; STREPTOKINASE; TRANDOLAPRIL; VERAPAMIL;

BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DRUG COST; DRUG HYPERSENSITIVITY; ELECTROCARDIOGRAM; EXERCISE TEST; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART SURGERY; HOSPITAL ADMISSION; HUMAN; LIFESTYLE; MORTALITY; OXYGEN THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; RISK BENEFIT ANALYSIS; SHORT SURVEY; STROKE; UNITED KINGDOM;

EID: 0034070972     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2000.38317     Document Type: Short Survey

References (60)

1. Chambless L, Keil U, Dobson A et al for the WHO MONICA Project. Population versus clinical view of case fatality from acute coronary heart disease. Results from the WHO MONICA Project 1985-1990. Circulation 1997; 96: 3849-59.
2. Norris RM on behalf of the United Kingdom Heart Attack Study Collaborative Group. Fatality outside hospital from acute coronary events in three British health districts, 1994-5. BMJ 1998; 316: 1065-70.
3. The United Kingdom Heart Attack Study (UKHAS) Collaborative Group. Effect of time from onset to coming under care on fatality of patients with acute myocardial infarction: effect of resuscitation and thrombolytic treatment. Heart 1998; 80: 114-20.
4. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349-60.
6. Eccles M, Freemantle N, Mason J and the North of England Aspirin Guideline Development Group. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. BMJ 1998; 316: 1303-9.
7. Oxygen in acute myocardial infarction. DTB 1977; 15: 10-2.
8. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.
9. Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-5.
10. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R on behalf of the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316: 1337-43.
11. Franzosi MG, Santoro E, De Vita C et al on behalf of the GISSI Investigators. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction. Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 Study. Circulation 1998; 98: 2659-65.
12. Should general practitioners give thrombolytic therapy? DTB 1994; 32: 65-6.
13. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990, 336: 71-5.
14. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
15. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
16. International Joint Efficacy Comparison of Thrombolytics. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346: 329-36.
17. The Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997, 337: 1118-23.
18. Joint Formulary Committee. British National Formulary Edition 39. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, March, 2000.
19. Menown IBA, Adgey AAJ. Improving reperfusion after myocardial infarction. BMJ 1999; 319: 1513-5 [editorial].
20. Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997, 336: 847-60.
21. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
22. Squire IB, Lawley W, Fietcher S et al. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J 1999; 20: 1245-52.
23. Weaver WD, Simes RJ, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. A quantitative review. JAMA 1997, 278: 2093-8.
24. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction (Cochrane Review). In: The Cochrane Library, Issue 1, 2000. Oxford: Update Software.
25. Nunn CM, O'Neill WW, Rothbaum D et al for The Primary Angioplasty in Myocardial Infarction I Study Group. Long-term outcome after primary angioplasty: report from the Primary Angioplasty in Myocardial Infarction (PAMI-I) Trial. J Am Coll Cardiol 1999; 33: 640-6.
26. Zijlstra F, Hoorntje JCA, de Boer M-J et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341: 1413-9.
27. Grines CL, Cox DA, Stone GW et al for the Stent Primary Angioplasty in Myocardial Infarction Study Group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999; 341: 1949-56.
28. Suryapranata H, van't Hof AWJ, Hoorntje JCA, de Boer M-J, Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998; 97: 2502-5.
29. Ellis SG, da Silva ER, Heyndrickx G et al for the RESCUE Investigators. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. Circulation 1994; 90: 2280-4.
30. Michels KB, Yusuf S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. Circulation 1995, 91: 476-85.
31. Donnelly R, Millar-Craig MW. Cardiac troponins: IT upgrade for the heart. Lancet 1998; 351: 537-9 [commentary].
32. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (suppl 2): S1-29
33. Madsen JK, Grande P, Saunamäki K et al on behalf of the DANAMI Study Group. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). Circulation 1997; 96: 748-55
34. NHS Centre for Reviews and Dissemination. Cardiac rehabilitation. Effective Health Care 1998; 4: 1-12.
35. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected myocardial infarction: ISIS-1. Lancet 1986; ii: 57-66.
36. Roberts R, Rogers WJ, Mueller HS et al for the TIMI Investigators Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991; 83: 422-37.
37. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.
38. Too many beta-blockers. DTB 1996; 34: 49-52.
39. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998, 97: 2202-12
40. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
41. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
42. Hall AS, Murray GD, Ball SG on behalf of the AIREX Study Investigators. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after myocardial infarction: AIRE Extension (AIREX) Study. Lancet 1997; 349: 1493-7.
43. Køber L, Torp-Pedersen C, Carlsen JE for the Trandolapnl Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-erzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
44. Toip-Pedersen C, Køber L for the TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after myocardial infarction. Lancet 1999; 354: 9-12.
45. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
46. Collins R, MacMahon S, Flather M et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials BMJ 1996; 313: 652-9.
47. Verheugt FWA. Acute coronary syndromes: drug treatments. Lancet 1999; 353 (suppl 11): 20-3.
48. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trimtrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
49. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816-9.
50. Magnesium, myocardial infarction, meta-analysis and megatrials. DTB 1995; 33: 25-7.
51. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993; 270: 1589-95.
52. Held PH, Yusuf S. Impact of calcium channel blockers on mortality. In: Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL (Eds). Cardiovascular pharmacology and therapeutics. New York: Churchill Livingstone, 1994.
53. Hennekens CH, Albert CM, Godftied SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials. N Engl J Med 1996; 335: 1660-7.
54. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990; 66: 779-85.
55. Gibson RS, Boden WE, Theroux P et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. N Engl J Med 1986; 315: 423-9.
56. Sadowski ZP, Alexander JH, Skrabucha B et al. Multicenter randomized trial and a systematic overview of lidocame in acute myocardial infarction. Am Heart J 1999; 137: 792-8.
57. Farré J, Romero J, Rubio JM, Ayala R, Castro-Dorticós J. Amiodarone and "primary" prevention of sudden death. critical review of a decade of clinical trials. Am J Cardiol 1999; 83: 55D-63D.
58. Elizari MV, Martinez JM, Belziti C et al. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction Eur Heart J 2000; 21: 198-205.
59. Malmberg K, Rydén L, Efendic S et al on behalf of the DIGAMI Study Group. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
60. Malmberg K for the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997; 314: 1512-5.